Abstract
The optimal therapy in patients with heart failure preserved ejection fraction (HFpEF) and hypertension (HT) has not been revealed. The beta blocker (BB) and the renin angiotensin aldosterone system inhibitor (RAAS-I) are recommend as class IIa in patients with HFpEF. The calcium channel blocker (CCB), a major anti-hypertensive drugs in Japan, is also recommend as class IIa in patients with HFpEF. However, the difference between azelnidipine, an L type CCB, and cilnidipine, an N type CCB, is unclear. We investigated the difference between azelnidipine and cilnidipine in patients with HFpEF and HT. Twenty-five consecutive HFpEF patients treated with BB and RAAS-I from April 2013 to March 2015 were enrolled. Initially, cilnidipine was used, and then switched to azelnidipine. Age, gender, blood pressure (BP), heart rate (HR), blood tests, echocardiography, and cardiac-scintigraphy ((123)I-metaiodobenzylguanidine: MIBG) were measured before and after six months from azelnidipine administration. There was no statistically significant difference in BP. B type natriuretic peptides were significantly reduced (pre-state: 195.4 ± 209.7 pg/ml and post-state: 140.7 ± 136.4 pg/ml, p = 0.050). In echocardiography, the TEI index tended to be ...Continue Reading
References
Jan 1, 1976·The American Journal of Cardiology·L E TeichholzR Gorlin
Jun 1, 1992·Trends in Pharmacological Sciences·W A Catterall, J Striessnig
Sep 1, 1989·Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography·N B SchillerI Schnittger
Oct 7, 2004·Circulation·Scott D SolomonMarc A Pfeffer
May 10, 2006·Journal of the American College of Cardiology·Sylvie A AhnMichel F Rousseau
Dec 28, 2006·Clinical and Experimental Hypertension : CHE·Yoshikuni KimuraKenji Sunagawa
Dec 6, 2008·Journal of Cardiovascular Pharmacology·Satomi KonnoKenji Sunagawa
Apr 3, 2009·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Seiichi MatsuoUNKNOWN Collaborators developing the Japanese equation for estimated GFR
May 27, 2010·Circulation Journal : Official Journal of the Japanese Circulation Society·Miyuki Tsuchihashi-MakayaUNKNOWN JCARE-CARD Investigators
Jan 7, 2011·Annals of Nuclear Medicine·Yoichi KuwabaraJunichi Yamazaki
May 24, 2011·European Journal of Heart Failure·Shinji HisatakeJunichi Yamazaki
Jul 15, 2011·International Journal of Hypertension·Kenichiro KinouchiHiroshi Itoh
Sep 13, 2011·Cardiovascular Diabetology·Kosuke FukaoHiroyuki Daida
Oct 23, 2012·Annals of Nuclear Medicine·Terufumi KinbaraSchinichiro Tanaka
May 11, 2013·Drug Design, Development and Therapy·Takeshi Takami, Yoshihiko Saito
Aug 16, 2013·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Kazuaki ShimamotoYusuke Ohya
Aug 31, 2013·Circulation Research·Anastasios LymperopoulosWalter J Koch
Apr 8, 2014·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Kazuaki ShimamotoUNKNOWN Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension
Mar 18, 2013·Journal of Diabetes Investigation·Hiroko AbeHirotaka Watada
Dec 3, 2014·Diabetes Research and Clinical Practice·Masami TanakaHiroshi Itoh
Jun 13, 2015·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Jagat NarulaArnold F Jacobson
Jun 21, 2015·The American Journal of Cardiology·Akira MaruiUNKNOWN CREDO-Kyoto CABG Registry Cohort-2 Investigators
Citations
Feb 27, 2018·Drug Discoveries & Therapeutics·Shunsuke KiuchiTakanori Ikeda
Apr 6, 2018·Heart Failure Reviews·Marijana TadicGuido Grassi
Feb 6, 2020·Clinical and Experimental Hypertension : CHE·Shunsuke KiuchiTakanori Ikeda
Oct 9, 2021·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Takeshi TakamiKazuomi Kario